Angiocrine Bioscience is a company that focuses on developing cellular therapies, specifically E-CEL therapies, which utilize the reparative powers of endothelial cells to positively impact patients' lives. The company's technology is based on breakthroughs in vascular biology and stem cell research, and it aims to restore and cure various diseases by harnessing the potential of endothelial cells and their role in tissue repair and regeneration. The company is currently conducting clinical trials, including a Phase 3 trial, to evaluate the efficacy and safety of its lead product, AB-205, in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation.

Angiocrine Bioscience is a private, clinical stage cell and gene therapy company based in San Diego, California. Angiocrine Bioscience began as a start-up located within Weill Cornell Medical College (New York City) and then relocated to San Diego, one of the leading regenerative biotechnology centers, in 2015. Angiocrine was started by notable and visionary scientists, physicians and entrepreneurs, funded and managed by US-based entrepreneurs.

Our company was built on over a decade of research in understanding how the human body naturally repairs and heals itself. Our scientific founders are pioneers in deducing the reparative role endothelial cells and endothelial-derived angiocrine factors which guide the body’s progenitor (stem) cells dispersed throughout various organs.

Angiocrine is developing a robust pipeline of Advanced Reparative Medicines. Advanced Reparative Medicines consist of engineered (genetically-modified) human cord endothelial (E-CEL®) cells that repair various damaged tissues and organs. Multiple E-CEL products are generated from Angiocrine’s E-CEL Platform: a proprietary R&D engine that creates multiple clinical product candidates.

Primary Endothelial Cells

Tissue specific human endothelial cells
Tissue specific mouse endothelial cells
Custom Services - endothelial cells from transgenic animals

2012